FDA Clears Dual-Head SPECT/CT System with Deep Learning Image Reconstruction
The combination of the Aurora SPECT/CT system with AI-enabled Clarify DL image reconstruction reportedly offers the potential of enhanced image quality and streamlined workflows in nuclear medicine.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Aurora single photon emission computed tomography/computed tomography (SPECT/CT) system and Clarify DL deep learning image reconstruction.
GE HealthCare, the developer of the dual-head Aurora SPECT/CT system, said the device offers the following key benefits:
The newly FDA-cleared dual-head Aurora SPECT/CT system has a 40 mm detector, which offers twice the coverage of CTs from other hybrid systems, and 128-slice capabilities across imaging applications in neurology, cardiology, and oncology, according to GE HealthCare, the developer of the Aurora SPECT/CT platform. (Image courtesy of GE HealthCare.)
• a 40 mm detector offering twice the coverage of CTs from other hybrid systems;
• 128-slice capabilities across imaging applications in neurology, cardiology, and oncology; and
• a 5/8-inch crystal Nal detector, which allows use of a variety of radiopharmaceuticals including theranostics.
Through advanced deep learning technology, GE HealthCare maintained that Clarity DL image reconstruction bolsters quality for bone SPECT imaging without the need for increased radiation dosing or scan time.
“Aurora’s seamless integration of SPECT and CT components will allow us to perform comprehensive, high-quality diagnostic exams in a single session, while its support of Clarify DL deep-learning image reconstruction enables enhanced image quality performance,” noted Donna Plecha, M.D., chair of the Department of Radiology at University Hospitals Cleveland Medical Center, and a professor of radiology at the Case Western Reserve University School of Medicine in Cleveland.
Recent Videos
Related Content
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025Article
The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025Article
In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025Article
For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
